Sterile solutions and peritoneal inflammation

Contributions to Nephrology

Volumn 150, Issue , 2006, Pages 156-165

  Flessner, Michael F ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIALYSIS FLUID; GLUCOSE; INTERLEUKIN 6;

EPITHELIUM CELL; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; REVIEW;

DIALYSIS SOLUTIONS; EPITHELIAL CELLS; GLUCOSE; HUMANS; INTERLEUKIN-6; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS;

EID: 33745245581     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000093516     Document Type: Review

References (43)

1. Dobbie JW, Anderson JD, Hind C: Long-term effects of peritoneal dialysis on peritoneal morphology. Perit Dial Int 1994;14(suppl 3):S16-S20.
2. Heimbürger O, Waniewski J, Werynski A: Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990;38:495-506.
3. Williams JD, Craig KJ, Topley N, Ruhland CV, Fallon M, Newman GR, Mackenzie RK, Williams GT: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-479.
4. Davies SJ, Bryan J, Phillips L, Russell GI: Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996;11:498-506.
5. Davies SJ, Phillips L, Naish PF, Russell GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal transport. J Am Soc Nephrol 2001;12:1046-1051.
6. Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-Carmona A, Vychytil A, MacNamara E, Ekstrand A, Tranaeus A, Filho JCD: Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005;67:1609-1615.
7. Chung SH, Heimbürger O, Stenvinkel P, Wang T, Lindholm B: Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int 2003;23:174-183.
8. Gillerot G, Goffin E, Michel C, Evenepoel P, Van Biesen W, Tintillier M, Stenvinkel P, Heimbürger O, Lindholm B, Nordfors L, Robert A, Devuyst O: Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int 2005;67:2477-2487.
9. Topley N: The cytokine network controlling peritoneal inflammation. Perit Dial Int 1995;5(suppl 7):S35-S46.
10. Brulez HFG, Verbrugh HA: First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Perit Dial Int 1995;15(suppl 7):S24-S34.
11. Margetts PJ, Bonniaud P: Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003;23:530-541.
12. Jorres A, Ludeat K, Sander K, Dunkel K, Lorenz F, Keck H: The peritoneal fibroblast and the control of peritoneal inflammation. Kidney Int 1996;50(suppl 56):S22-S27.
13. Hollenberg SM, Cunnion RE, Parillo JE: The effect of tumor necrosis factor on vascular smooth muscle; in vitro study using aortic rings. Chest 1991;100:1133-1137.
14. Ferrier M-L, Combet S, Landshoot MV, Stoenoiu MS, Cnops Y, Lamière N, Devuyst O: Inhibition of nitric oxide synthase reverses changes in peritoneal permeability in a rat model of acute peritonitis. Kidney Int 2001;60:2343-2350.
15. Yi ES, Ulich TR: Endotoxin, interleukin-1, and tumor necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules. Am J Pathol 1992;140:659-663.
16. Saulpaw CE, Joyner WL: Bradykinin and tumor necrosis factor-alpha alter albumin transport in vivo: a comparative study. Microvas Res 1997;54:221-232.
17. Abe Y, Sekiya S, Yamasita T, Sendo F: Vascular hyperpermeability induced by tumor necrosis factor and its augmentation by IL-1 and IFN is inhibited by selective depletion of neutrophils with a monoclonal antibody. J Immunol 1990;145:2902-2907.
18. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramierez-Huesca M, Dominguez-Jimenez C, Jmienez-Herrernan JA, et al: Peritoneal dialysis and epithelial-to- mesenchymal transition of mesothelial cells. New Engl J Med 2003;348:403-413.
19. Bos HJ, van Bronswijk H, Heimerhorst TJ, Oe PL, Hoefsmit EC, Beelen RH: Distinct subpopulations of elicited human macrophages in peritoneal dialysis patients and women undergoing laparoscopy: a study on peroxidatic activity. J Leukocyte Biol 1988;43:172-178.
20. Shostak A, Pivnik E, Gotloib L: Cultured rat mesothelial cells generate hydrogen peroxide: a new player in peritoneal defense? J Am Soc Nephrol 1996;7:2371-2378.
21. Topley N, Mackenzie RK, Petersen MM, Beavis MJ, Williams D, Thomas N, Faict D, Peluso F, Coles GA: In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid. Nephrol Dial Transplant 1991;6:574-581.
22. Liberek T, Topley N, Mistry CD, Coles GA, Morgan T, Quirk RA, Williams JD: Cell function and viability in glucose polymer peritoneal dialysis fluids. Perit Dial Int 1993;13:104-111.
23. Flessner MF: Transport of water-soluble solutes between the peritoneal cavity and plasma in the rat ann arbor, MI, University of Michigan, 1981.
24. Jörres A, Topley N, Steenweg L, Muller C, Kottgen E, Gahl GM: Inhibition of cytokine sythesis by peritoneal dialysate persists throughout the CAPD cycle. Am J Nephrol 1992;12:80-85.
25. Ha H, Cha MK, Choi HN, Lee HB: Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002;22:171-177.
26. Jones S, Holmes C, Krediet RT, Mackenzie RK, Faict D, Tranaeus A, Williams JD, Coles GA, Topley N: Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001;59:1529-1538.
27. Ha H, Yu MR, Lee HB: High glucose-induced PKC activation mediates TGF-Beta1 and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int 2001;59:463-470.
28. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jorres A: Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000;11:729-739.
29. Mortier S, deVriese AS, Van deVoorde J, Schaub TP, Passlick-Deetjen J, Lameire NH: Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 2002;13:1419-1422.
30. Combet S, Miyata T, Moulin P, Pouthier D, Goffin E, Devuyst O: Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol 2000;11:717-728.
31. Zweers MM, Struijk DG, Smit W, Krediet RT: Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up. J Lab Clin Med 2001;137:125-132.
32. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ: Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005;16:1471-1485.
33. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J: The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408-418.
34. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim YL, Kim DJ, Kim YS, Ahn C, Kim MJ, Shin SK: Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (balance). Perit Dial Int 2005;25:248-255.
35. Wieczorowska-Tobis K, Brelinska R, Witowski J, Passlick-Deetjen J, Schaub T, Schilling H, Breborowicz A: Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products. Perit Dial Int 2004;24:48-57.
36. Mortier S, Faict D, Lameire NH, deVriese AS: Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 2005;67:1559-1565.
37. Musi B, Braide M, Carlsson O, Wieslander A, Albrektsson A, Ketteler M, Westenfeld R, Floege J, Rippe B: Biocompatibility of peritoneal dialysis fluids: long-term exposure of nonuremic rats. Perit Dial Int 2004;24:37-47.
38. Zareie M, van Lambalgen AA, ter Wee PM, Hekking LHP, Keuning ED, Schadee-Eestermans IL, Faict D, Degreve B, Tangelder G-J, Beelen RHJ, van den Born J: Better preservation of the peritoneum in rats exposed to amino acid-based peritoneal dialysis fluid. Perit Dial Int 2005;25:58-67.
39. Wu G, Wieczorowska-Tobis K, Polubinska A, Korybalska K, Filas V, Tam P, French I, Breborowicz A: N-Acetylglucosamine changes permeability of peritoneum during chronic peritoneal dialysis in rats. Perit Dial Int 1988;18:217-224.
40. Polubinska A, Pawlaczyk K, Kuzlan-Pawlaczyk M, Wieczorowska-Tobis K, Chen C, Moberly JB, Martis L, Breborowicz A, Oreopoulos D: Dialysis solution containing hyaluronan: effect on peritoneal permeability and inflammation in rats. Kidney Int 2000;57:1182-1189.
41. Wieczorowska-Tobis K, Breborowicz A, Martis L, Oreopoulos D: Protective effect of hyaluronic acid against peritoneal injury. Perit Dial Int 1995;15:81-83.
42. Wang T, Cheng HH, Heimbürger O, Chen C, Waniewski J, Bergström J, Lindholm B: Hyaluronan decreases peritoneal fluid absorption: effect of molecular weight and concentration of hyaluronan. Kidney Int 1999;55:667-673.
43. Beavis MJ, Williams JD, Hoppe J, Topley N: Human peritoneal fibroblast proliferation in 3-dimensional culture: modulation by cytokines, growth factors and peritoneal dialysis effluent. Kidney Int 1997;51:205-215.